Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder. Due to lack of response to the medication and significant side effects of the treatment with stimulants, alternative medications should be considered. The aim of this study is to evaluate efficacy of agomelatine in treatment of ADHD.
Methods:
Fifty-four outpatients, children 6–15 years old, with diagnosis of ADHD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria participated in a 6-week, parallel, double-blind, randomized clinical trial. Fifty patients completed 6 weeks of treatment with either ritalin (methylphenidate hydrochloride [MPH]) (20 mg/day in participants below 30 kg and 30 mg/day in patients with weight ≥30 kg) or agomelatine (15 mg/day in patients with weight ≥30 kg and 25 mg/day in patients with weight ≥45 kg). Participants were assessed using Parent and Teacher ADHD Rating Scale-IV at baseline and at weeks 3 and 6.
Results:
General linear model repeated measures showed no significant differences between the two groups on Parent and Teacher Rating Scale scores (F = 1.13, df = 1.26, p = 0.305, and F = 0.95, df = 1.25, p = 0.353, respectively). Changes in Teacher and Parent ADHD Rating Scale scores from baseline to the study end were not significantly different between the agomelatine group (9.28 ± 8.72 and 24.12 ± 7.04, respectively) and the MPH group (6.64 ± 11.04 and 25.76 ± 7.82, respectively) (p = 0.46 and p = 0.44, respectively). There was a trend for less insomnia in the agomelatine group versus MPH-treated group (4% vs. 24%, p = 0.09).
Conclusions:
A treatment course of 6 weeks with agomelatine demonstrated a favorable safety and efficacy profile in children and adolescents with ADHD. Nonetheless, larger controlled studies with longer treatment periods are necessary.
Get full access to this article
View all access options for this article.
References
1.
AbbasiSH, HeidariS, MohammadiMR, TabriziM, GhaleihaA, AkhondzadehS: Acetyl-L-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: A placebo-controlled trial. Child Psychiatry Hum Dev, 42:367–375, 2011.
2.
AkhondzadehS, TavakolianR, Davari-AshtianiR, ArabgolF, AminiH: Selegiline in the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry, 27:841–845, 2003.
3.
AlamoC, Lopez-MunozF, Garcia-GarciaP: Melatonin Theraputic Value and Neuroprotection. Boca Raton (Florida), CRC Press, 2014.
4.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., Revised. Washington, DC: American Psychiatric Association; 1987.
5.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
6.
AmiriS, MohammadiMR, MohammadiM, NouroozinejadGH, KahbaziM, AkhondzadehS: Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: A double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry, 32:145–149, 2008.
7.
AvilaA, CardonaX, Martin-BaraneraM, LeonL, CaballolN, MilletP, BelloJ: Agomelatine for depression in Parkinson disease: Additional effect on sleep and motor dysfunction. J Clin Psychopharmacol, 35:719–723, 2015.
8.
BlierP, El MansariM: Serotonin and beyond: Therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci, 368:20120536, 2013.
9.
ChungYC, LeeCR, ParkTW, YangKH, KimKW: Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: An open-label trial. World J Biol Psychiatry, 10:156–162, 2009.
10.
CooganAN, ThomeJ: Chronotherapeutics and psychiatry: Setting the clock to relieve the symptoms. World J Biol Psychiatry, 12Suppl 1:40–43, 2011.
11.
CormierE: Attention deficit/hyperactivity disorder: A review and update. J Pediatr Nurs, 23:345–357, 2008.
12.
CuratoloP, PalosciaC, D'AgatiE, MoaveroR, PasiniA: The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol, 13:299–304, 2009.
13.
DopheideJA, PliszkaSR: Attention-deficit-hyperactivity disorder: An update. Pharmacotherapy, 29:656–679, 2009.
14.
DuPaulGJ, PowerTJ, AnastopoulosAD, ReidR: ADHD Rating Scale—IV: Checklists, Norms, and Clinical Interpretation. New York, Guilford Press, 1998.
15.
FornaroM, PrestiaD, ColicchioS, PerugiG: A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol, 8:287–304, 2010.
16.
GhanizadehA, MohammadiMR, YazdanshenasA: Psychometric properties of the Farsi translation of the kiddie schedule for affective disorders and schizophrenia-present and lifetime version. BMC Psychiatry, 6:10, 2006.
17.
GoldMS, BlumK, Oscar-BermanM, BravermanER: Low dopamine function in attention deficit/hyperactivity disorder: Should genotyping signify early diagnosis in children?. Postgrad Med, 126:153–177, 2014.
18.
GruberR, FontilL, BergmameL, WiebeST, AmselR, FrenetteS, CarrierJ: Contributions of circadian tendencies and behavioral problems to sleep onset problems of children with ADHD. BMC Psychiatry, 12:212, 2012.
19.
ImerajL, Sonuga-BarkeE, AntropI, RoeyersH, WiersemaR, BalS, DeboutteD: Altered circadian profiles in attention-deficit/hyperactivity disorder: An integrative review and theoretical framework for future studies. Neurosci Biobehav Rev, 36:1897–1919, 2012.
20.
JafariniaM, MohammadiMR, ModabberniaA, AshrafiM, KhajaviD, TabriziM, YadegariN, AkhondzadehS: Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: Randomized double-blind study. Hum Psychopharmacol, 27:411–418, 2012.
21.
KahbaziM, GhoreishiA, RahiminejadF, MohammadiMR, KamalipourA, AkhondzadehS: A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res, 168:234–237, 2009.
22.
MohammadiM, AkhondzadehS: Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy. Acta Med Iran, 49:487–498, 2011.
MohammadiMR, HafeziP, GaleihaA, HajiaghaeeR, AkhondzadehS: Buspirone versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: Randomized double-blind study. Acta Med Iran, 50:723–728, 2012.
25.
MohammadiMR, KazemiMR, ZiaE, RezazadehSA, TabriziM, AkhondzadehS: Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: A randomized, double-blind trial. Hum Psychopharmacol, 25:560–565, 2010.
26.
Molina-CarballoA, Naranjo-GomezA, UberosJ, Justicia-MartinezF, Ruiz-RamosMJ, Cubero-MillanI, Contreras-ChovaF, Augustin-MoralesMD, Khaldy-BelkadiH, Munoz-HoyosA: Methylphenidate effects on blood serotonin and melatonin levels may help to synchronise biological rhythms in children with ADHD. J Psychiatr Res, 47:377–383, 2013.
27.
NaguyA, Al-MutairiH: Agomelatine augmenting partial stimulant response in ADHD and mitigating stimulant-induced insomnia and anxiety. J Child Adolesc Behav, 3:208, 2015.
28.
NavaillesS, De DeurwaerdereP, PorrasG, SpampinatoU: In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum. Neuropsychopharmacology, 29:319–326, 2004.
29.
NiederhoferH: Treating ADHD with agomelatine. J Atten Disord, 16:346–348, 2012.
30.
PolanczykG, de LimaMS, HortaBL, BiedermanJ, RohdeLA: The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry, 164:942–948, 2007.
QuesseveurG, NguyenHT, GardierAM, GuiardBP: 5-HT2 ligands in the treatment of anxiety and depression. Expert Opin Investig Drugs, 21:1701–1725, 2012.
33.
RacagniG, RivaMA, MolteniR, MusazziL, CalabreseF, PopoliM, TarditoD: Mode of action of agomelatine: Synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry, 12:574–587, 2011.
34.
SalehiB, ImaniR, MohammadiMR, FallahJ, MohammadiM, GhanizadehA, TasviechiAA, VossoughiA, RezazadehSA, AkhondzadehS: Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: A double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry, 34:76–80, 2010.
35.
SanL, ArranzB: Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry, 23:396–402, 2008.
36.
SnitselaarMA, SmitsMG: Sleep, melatonin, and circadian rhythmicity in attention deficit hyperactivity disorder. In: Melatonin and Melatonergic Drugs in Clinical Practice. Edited by SrinivasanV, BrzezinskiA, OterS, DshilcuttS.India, Springer, 2014, pp. 379–384.
37.
Tehrani-DoostM, MoallemiS, ShahrivarZ: An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 18:179–184, 2008.
38.
ZarinaraAR, MohammadiMR, HazratiN, TabriziM, RezazadehSA, RezaieF, AkhondzadehS: Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: A randomized, double-blind comparison trial. Hum Psychopharmacol, 25:530–535, 2010.
